Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

Strong financial position supports clinical focus on advancing drug

candidates for treatment of lysosomal storage disorders

CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the first quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.34 per share ($0.28 per share on a non-GAAP basis) for the three months ended March 31, 2008. As of March 31, 2008, cash, cash equivalents, and marketable securities totaled $154.6 million.

"In the first quarter of 2008, we continued to advance our three lead clinical development programs. We also reported data from multiple clinical trials that add to the growing body of evidence demonstrating that treatment with our oral pharmacological chaperone drug candidates has the potential to benefit patients with Fabry, Gaucher and Pompe disease," said John F. Crowley, President and CEO of Amicus Therapeutics. "In the months ahead in 2008, we will be focused on advancing the global regulatory plan for Amigal Phase 3 development, evaluating opportunities for additional clinical studies in Gaucher and Pompe disease, as well as on identifying new therapeutic areas for applying our pharmacological chaperone technology platform."

Program Advancements

Fabry Disease:

Amigal(TM) (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. In March, clinical investiga
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... (PRWEB) September 20, 2014 MediVet ... to perform a groundbreaking surgery at the specialized Wolvega ... mare's superficial digital flexor tendon was ruptured 90% and ... of injury is a death sentence for a horse. ... stem cell treatments . This revolutionary regenerative ...
(Date:9/19/2014)... to disease risks, the biological characteristics people care most ... for heightthe textbook example of a complex traitattributes like ... multiple genetic and environmental influences, making it challenging to ... geneticists typically mate two individuals that differ in key ... then study their descendents, looking for genes that tend ...
(Date:9/19/2014)... Chips that use light, rather than electricity, to ... and energy efficiency is a growing concern as ... chief components of optical circuits light emitters, ... to build. One promising light source for optical ... optical properties when deposited as a single, atom-thick ...
(Date:9/19/2014)... YORK , Sept. 19, 2014  An entire ... forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) – ... and legs, causing extreme muscle atrophy, weakness, and foot ... the US and millions worldwide. CMT is a progressive ... of their legs, requiring mobility devices such as leg ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Want to link genes to complex traits? Start with more diversity 2Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2
... 15, 2006, the Supreme Court in eBay Inc. v. ... proves infringement should be granted an injunction must be ... (1) irreparable injury; (2) inadequacy of remedies at law; ... The Court rejected the Federal Circuit's approach that an ...
... encounter, we reviewed the list of the leading Big Pharma companies of ... some of the leading pharmaceuticals products and deals of 2005. , ... Product/Company Disease Area ... Lipitor (Pfizer) Cholesterol Reduction $12.9 +6% ...
... Inc., a developer of protein chip technologies, has ... the National Institutes of Health to develop a test ... ,An estimated 50 million Americans suffer from mild to ... especially for children and senior citizens. GenTel's protein chips ...
Cached Biology Technology:Supreme Court decision in eBay case could affect value of patents 2Big Pharma's continued hunger and search for new products 2Big Pharma's continued hunger and search for new products 3Big Pharma's continued hunger and search for new products 4GenTel gets federal grant to develop allergy test 2GenTel gets federal grant to develop allergy test 3
(Date:9/19/2014)... the sake of fairness per se but in order ... Frans de Waal, PhD, and Sarah Brosnan, PhD, co-authors ... is defined as a negative reaction to unequal outcomes. ... , Their conclusion comes after the co-authors reviewed more ... it is the evolution of forestalling partner dissatisfaction with ...
(Date:9/19/2014)... study shows that legume plants regulate their symbiotic ... that are transmitted through the plant structure from ... of bacteria-holding nodules in the roots. This collaborative ... Institute for Basic Biology, the Graduate University for ... Sustainable Resource Science in Japan. , Legumes, ...
(Date:9/18/2014)... A sleep-promoting circuit located deep in the primitive ... Discovered by researchers at Harvard School of Medicine and ... Sciences, this is only the second "sleep node" identified ... both necessary and sufficient to produce deep sleep. , ... the study demonstrates that fully half of all of ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3For legume plants, a new route from shoot to root 2No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... number of rivers and lakes are being invaded by exotic ... Such species represent a threat to native species, as they ... the case of the mudsnail Potamopyrgus antipodarum ... and has spread throughout rivers, lakes or streams in Europe, ...
... found that silicone foul release coatings may be an important ... water and hydropower infrastructure. Allen D. Skaja, Ph.D., PCS, of ... metal alloys over three years at Parker Dam on the ... to reduce the rate of mussel settlement, and any attached ...
... Calif. ( www.ucr.edu ) Research by Nosang ... Riverside, Bourns College of Engineering, has enabled a ... that can detect small quantities of harmful airborne ... Economy Corporation company, has completed the prototype which ...
Cached Biology News:Survival without water: A key trait of an aquatic invader to spread 2'Electronic nose' prototype developed 2
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
SHEEP ANTI FLECAINIDE...
ANTI PIG LDH H4...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: